Phase II trial of the oral PARP inhibitor olaparib (AZD2281) in BRCA-deficient advanced ovarian cancer

Published on Sep 22, 2016in Journal of Clinical Oncology28.349
M. W. Audeh2
Estimated H-index: 2
Richard T. Penson47
Estimated H-index: 47
+ 6 AuthorsAndrew Tutt56
Estimated H-index: 56
5500 Background: Olaparib (AZD2281; KU-0059436) is a novel, orally active PARP inhibitor that induces synthetic lethality in homozygous BRCA-deficient cells. A phase I trial identified 400 mg bd as the maximum tolerated dose (MTD) with an initial signal of efficacy in BRCA-deficient cancers (ASCO 2008; abst 5510). The primary aim of this study was to test the efficacy of olaparib in confirmed BRCA1/BRCA2 carriers with advanced chemotherapy-refractory ovarian cancer. The secondary aim was to assess the safety and tolerability profile in ovarian cancer patients with BRCA1/2 deficiency. Methods: In an international, multicenter, proof-of-concept, single-arm, phase II study, two patient (pt) sequential cohorts received continuous oral olaparib in 28-day cycles, initially at the MTD, 400 mg bd (33 pts), and subsequently at 100 mg bd (24 pts), a previously shown clinically active and PARP inhibitory dose. Eligibility criteria included confirmed genetic BRCA1/2 mutation and recurrent, measurable, incurable disea...
  • References (0)
  • Citations (94)
📖 Papers frequently viewed together
14 Authors (Hannah Farmer, ..., Alan Ashworth)
3,482 Citations
2,378 Citations
10 Authors (Helen E. Bryant, ..., Thomas Helleday)
2,664 Citations
78% of Scinapse members use related papers. After signing in, all features are FREE.
Cited By94
#1Esha Sachdev (Cedars-Sinai Medical Center)H-Index: 6
#2Roya Tabatabai (Cedars-Sinai Medical Center)H-Index: 2
Last. Monica Mita (Cedars-Sinai Medical Center)H-Index: 14
view all 5 authors...
PARP (poly(ADP-ribose) polymerase) inhibitors represent a novel class of anti-cancer therapy; they take advantage of synthetic lethality and induce cell death by exploiting a defect in DNA repair. This class of medication was initially evaluated in patients with BRCA-associated tumors, but efficacy was also demonstrated in other populations. Since 2014, four PARP inhibitors have been approved in various indications: olaparib, niraparib, and rucaparib in high-grade serous ovarian cancer, and olap...
9 CitationsSource
Abstract The complexity of cancer chemotherapy requires pharmacists be familiar with the complicated regimens and highly toxic agents used. This column reviews various issues related to preparation, dispensing, and administration of antineoplastic therapy, and the agents, both commercially available and investigational, used to treat malignant diseases. Questions or suggestions for topics should be addressed to Dominic A. Solimando, Jr, President, Oncology Pharmacy Services, Inc., 4201 Wilson Bl...
1 CitationsSource
#1Alison Wiggans (Musgrove Park Hospital)H-Index: 1
#2Gemma K S Cass (Musgrove Park Hospital)H-Index: 1
Last. Jo Morrison (Musgrove Park Hospital)H-Index: 9
view all 5 authors...
Background Ovarian cancer is the sixth most common cancer and seventh most common cause of cancer death in women world-wide. Three-quarters of women present when the disease has spread throughout the abdomen (stage III or IV) and treatment consists of a combination of debulking surgery and platinum-based chemotherapy. Although initial responses to chemotherapy are good, most women will relapse and require further chemotherapy and will eventually develop resistance to chemotherapy. PARP (poly (AD...
21 CitationsSource
El cancer de prostata (PCa) es la segunda causa de muerte por cancer en los hombres en la poblacion argentina. El instituto Nacional del Cancer (USA) describe diferentes tratamientos para los pacientes con PCa: cirugia, radiacion y hormono-terapia. Para los pacientes con PCa avanzado, el tratamiento mas comun es el docetaxel, sin embargo esta terapia no extiende significativamente la sobrevida de los pacientes. Por lo tanto, es critico el desarrollo de nuevos agentes y combinaciones para el trat...
#2J. Aubrey WaddellH-Index: 3
Last. Alexander ParkwayH-Index: 1
view all 6 authors...
#1Peter StephensH-Index: 5
#2Ruth PlummerH-Index: 32
#1Kara N. Maxwell (UPenn: University of Pennsylvania)H-Index: 17
#2Susan M. Domchek (UPenn: University of Pennsylvania)H-Index: 64
The most well recognized breast cancer susceptibility genes are BRCA1 and BRCA2. Studies in individuals carrying mutations in these genes have led to clinical care guidelines for screening and prevention. Beyond BRCA1 and BRCA2, mutations in TP53, PTEN, STK11, and CDH1 also significantly increase the risk of breast cancer. Early identification of women at increased risk of breast cancer due to specific genetic susceptibility may lead to enhanced screening and prevention strategies and potentiall...
7 CitationsSource
#1Gonzalo TapiaH-Index: 1
#2Ivan Diaz-PadillaH-Index: 1
In 2012, approximately 22,280 women will be diagnosed with ovarian carcinoma in the United States and roughly 15,500 will die from this disease, ranked the most common cause of death among gynecologic malignancies in developed countries [1]. Most women with epithelial ovarian cancer (EOC) present with advanced disease (stage III or IV) at the time of diagnosis. This phenomenon is mainly due to the lack of specific symptoms until disease has spread beyond the ovaries, at which time the chance of ...
11 CitationsSource
Objectives To review the available systemic treatments for women with recurrent ovarian cancer.
12 CitationsSource